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Abstract We have previously isolated the efp (estrogen-
responsive finger protein) that is required for the normal
estrogen-induced cell proliferation. Here, we show the genomic
organization of the human efp gene which consists of nine exons.
The efp mRNA was expressed in human breast tumors and the
estrogen-induced expression of the efp was found in MCF-7
human breast cancer cells. Moreover, efp promoter activity was
enhanced through the estrogen-responsive element dependent on
estrogen and estrogen receptor. These results suggest that the efp
can mediate estrogen actions such as cell growth in human breast
cancer as a primary responsive gene.
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1. Introduction
Estrogen plays important roles in the development/matura-
tion of the female reproductive organs and sexual behavior
[1]. Estrogen is also involved in cell cycle progression and
generation/promotion of tumors such as breast, uterus and
prostate cancers [2,3]. Estrogen actions are assumed to be
mediated by estrogen receptors (ERK and L) which regulate
the transcription of target genes [1]. Therefore, uncovering the
regulation and function of estrogen-responsive genes must
lead to the clari¢cation of the molecular mechanism of estro-
gen action in target tissues including breast cancer.
Estrogen-responsive ¢nger protein (efp), a member of the
RING ¢nger family, has been isolated by genomic binding site
cloning using a recombinant ER protein [4]. The efp gene has
an estrogen-responsive element (ERE) at the 3P-untranslated
region (UTR) and is predominantly expressed in female re-
productive organs including uterus, ovary and mammary
gland [4,5]. Estrogen-induced expression is found in the ute-
rus, brain and mammary gland cells [4,5]. It is revealed that
estrogen responses are markedly attenuated in uterus of efp
knockout mice, suggesting that efp is essential for estrogen-
induced cell growth [6]. Therefore, we have inferred that the
efp mediates some estrogen actions in target organs [4^6].
We previously analyzed the 5P-£anking region of the human
efp gene [7] and demonstrated that the region 3173 to 31
relative to the translation initiation site had full promoter
activity. In this region, an E-box element which bound the
upstream stimulatory factor (USF) was indispensable for ba-
sic promoter activity. A GC-rich region with three putative
GC-boxes adjacent to the E-box contained a positive regula-
tory region (3120 to 3110) where an unknown factor(s)
bound. In the mouse efp promoter, both the E-box and the
GC-rich positive regulatory region were well conserved [8].
Besides, a negative regulatory region was revealed upstream
of the promoter region of the human efp gene [7].
In the present study, we describe the structure of the human
efp gene, and its expression and estrogen-induced promoter
activity in human breast cancer cells.
2. Materials and methods
2.1. Breast tumor samples and cell culture
Fifteen samples of human breast tissues were collected from pa-
tients. Tumor tissues and adjacent normal tissues were obtained
from the same resection specimen. Informed consent was obtained
from all patients and permission was obtained from the local Ethical
Committee. MCF-7 cells derived from a human breast cancer and
293T cells derived from a human embryonic kidney cell line trans-
formed with SV40 large T antigen were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) medium with 10% fetal calf serum
(FCS) at 37‡C in 5% CO2 and a humidi¢ed atmosphere. To inves-
tigate estrogen responsiveness of efp mRNA, MCF-7 cells were main-
tained in phenol red-free DMEM containing 0.5% dextran-coated
charcoal-treated FCS for 48 h. Subsequently the medium was changed
to one containing or not containing 1038 M 17L-estradiol and the
cells were harvested at indicated times to isolate total RNA.
2.2. RNA extraction and RNase protection assay
Total RNA was extracted from breast tumor tissues and adjacent
normal tissues and MCF-7 cells using Isogen (Nippongene, Toyama,
Japan) and the RNase protection assay was performed using an RPA
II kit (Ambion, Austin, TX, USA) [7]. Total RNA (20 Wg) was hy-
bridized with efp and GAPDH RNA probes described elsewhere [5].
Hybridization signals were quanti¢ed using the BAS 2000 phospho-
imaging system (Fuji, Inc.). The signal intensities of efp (330 bp) and
GAPDH (114 bp) were measured using the same area, respectively,
and the values of efp signals were divided by the corresponding one of
GAPDH to normalize them. Statistical analysis was done using
Sche¡e¤’s F test.
2.3. Chloramphenicol acetyltransferase (CAT) assay
Oligonucleotides 5P-CCGCTCGAGTTCAGGGTCATGGTGAC-
CCTGATCTCGAGCGG-3P and 5P-CCGCTCGAGATCAGGGT-
CACCATGACCCTGAACTCGAGCGG-3P containing the ERE of
the 3P-UTR of the human efp gene [4] were annealed and inserted
into the XhoI site of pMSG-CAT (Pharmacia, Piscataway, NJ, USA)
self-ligated with BamHI to delete the NEO coding sequence (pMSG-
CATERE). The human efp promoter regions of CAT reporter plas-
mids (pCAThe-235, pCAThe-173, pCAThe-120, pCAThe-114) de-
scribed previously [7] were transferred to pMSG-CATERE. They
were designated pCAThe-235ERE, pCAThe-173ERE, pCAThe-
120ERE and pCAThe-114ERE, respectively. pCAThe-173mutERE1
and pCAThe-173mutERE2 which contained 2 bp mutations:
TTTCATGGTGACC in a half-site and 4 bp mutations:
TTTCATGGTGATT in both half-sites of the ERE of the 3P-UTR
of the human efp gene, respectively, were constructed like pCAThe-
173ERE except for using the corresponding mutated oligonucleotides.
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Oligonucleotides 5P-CCGCTCGAGCCCGAGGGCAGGGTGACC-
TCCTGCTCGAGCGG-3P and 5P-CCGCTCGAGACGGAGGTCA-
CCCTGCCCTAGGGCTCGAGCGG-3P containing the ERE of the
3P-UTR of the mouse efp gene were used to construct pCAThe-
173mERE. The CAT assay was performed as described [9].
3. Results
3.1. Structural organization of the efp gene
During a database search, we noted that a sequence of
chromosome 17 (clone hRPC1107 A 17, accession number
AC004584) deposited in GenBank contained the full length
of the efp cDNA. Comparison between the cDNA and the
chromosome 17 sequence revealed the genomic organization
of the efp gene (Fig. 1). The human efp gene expands approx-
imately 25 kb of genomic DNA and consists of nine exons
and eight introns. The ¢rst methionine codon of the open
reading frame is located in exon 1, whereas the stop codon
and poly(A) addition signal are located in the last exon 9
which contained the whole 3P-UTR. Fig. 1B schematically
shows the efp cDNA with nine exons and coding regions
for the conserved domains below. RING ¢nger (R) and B1
box (B1) and B2 box (B2) domains were encoded in exon 1,
the coiled-coil domain (C-C) ranged from the end of exon 1 to
exon 4 and the C-terminal domain (C) located in the N-ter-
minal portion of exon 9. The sequences of exon/intron junc-
tions are shown in Fig. 1C. All exon/intron boundaries con-
form to the consensus donor/acceptor sequence (gt/ag) for
RNA splicing.
3.2. Expression of efp in breast cancer
To investigate the expression of efp mRNA in human
breast cancer, an RNase protection assay was performed us-
ing total RNAs isolated from breast tumor tissues and adja-
cent normal tissues. RNA probes for efp and GAPDH were
degraded with RNase digestion and gave speci¢c protected
signals of efp (330 bp) and GAPDH (114 bp), respectively.
Some smaller background bands which may be caused by
degradation of the probe or the protected fragment were
seen [10,11]. Efp mRNA was expressed in all 15 samples
tested. Although the amount of mRNA in a tumor relative
to adjacent normal tissue varied among the specimens, efp
mRNA expression of the tumor tissue was greater than that
of the adjacent normal tissue in nine of 15 samples. In partic-
ular, there were two instances where the expression of the efp
in tumor tissue was elevated more than twice (Fig. 2).
3.3. Estrogen responsiveness of efp mRNA and promoter
activity
Since MCF-7 cells derived from human breast cancer
mainly express ERK and are known to respond to estrogen
[12], we investigated the estrogen responsiveness of efp
Fig. 1. Gene structure of efp. A: Genomic organization of the human efp gene. Exons are shown as boxes. The ¢lled and open boxes indicate
the coding and non-coding sequences, respectively. Exon sizes are also shown. B: cDNA structure of human efp. The boxes correspond to the
exons shown in A in order. C: Exon/intron splice junction sequences.
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mRNA using this cell line. Total RNAs were extracted from
MCF-7 cells treated with or without estrogen and an RNase
protection assay was performed. The induction rates of the
efp mRNA levels were plotted (Fig. 3A). The expression of
the efp mRNA was elevated by estrogen treatment within
0.5 h and reached a peak (about 1.7 times) at 1 h. The ex-
pression level of efp mRNA returned to the level before treat-
ment at 8 h. Thus, the estrogen induction of efp mRNA was
con¢rmed in MCF-7 cells.
Subsequently, we analyzed the estrogen responsiveness of
the efp promoter using the CAT assay in this cell line (Fig.
3B). Since we have found that the negative and positive reg-
ulatory regions and an E-box are important for transcription
regulation [7], the sequence 3235 to 31 relative to the trans-
lation initiation site containing all these elements, the se-
quence 3173 to 31 not containing the negative regulatory
region, the sequence 3120 to 31 containing the positive reg-
ulatory region together with the E-box, and the sequence
3114 to 31 containing only the E-box were constructed
with the ERE of the efp in the 3P-UTR. The results are shown
in Fig. 3B. pCAThe-173ERE, which had about ¢ve times
higher activity than pCAThe-114ERE without estrogen, was
enhanced three times by estrogen treatment. These results
show the ERE in the 3P-UTR functions as an enhancer in
response to estrogen treatment. However, pCAThe-120ERE
and pCAThe-114ERE did not show signi¢cant estrogen-in-
duced activities, indicating that the promoter region 3173
to 31 is needed to respond to estrogen. The activity of
pCAThe-235ERE was not enhanced by estrogen, suggesting
that the negative regulatory region 3235 to 3174 has strong
silencer activity.
3.4. ERE of efp responds to both ERK and ERL and the
mutations thereof attenuate the enhancing activity
Next, we examined whether the efp promoter/enhancer
could respond to ERK or ERL. 293T cells that do not express
either ER were transiently cotransfected with ERK or ERL
expression plasmids and assayed for CAT activities (Fig. 4).
When no ER expression vector was cotransfected, estrogen-
induced promoter activities were not observed and the pat-
terns were similar to that of MCF-7 without estrogen. On the
other hand, estrogen-induced activities of pCAThe-173ERE,
pCAThe-120ERE and pCAThe-114ERE were indicated if not
only the ERK but also the ERL expression vector was cotrans-
fected. Since estrogen-induced activities of pCAThe-120ERE
and pCAThe-114ERE were obviously lower than that of
pCAThe-173ERE and were observed only after the ER ex-
pression vectors were cotransfected, the sequence 3173 to
31 of the efp promoter is necessary for the entire activity
through the ERE in the 3P-UTR. To con¢rm the function
of the ERE in the 3P-UTR, mutated ERE sequences were
introduced into pCAThe-173ERE (see Section 2) (Fig. 5).
pCAThe-173mutERE1 containing a 2 bp mutation in a half-
site of the ERE possessed about half of the activity to respond
to estrogen compared to pCAThe-173ERE; on the other
hand, pCAThe-173mutERE2 containing a 4 bp mutation in
both half-sites of the ERE could hardly respond to estrogen
either in MCF-7 cells or 293T cells cotransfected with ERK or
ERL. These results indicate that the ERE in the 3P-UTR is
Fig. 2. Expression of efp mRNA in human breast cancer. RNase
protection assay was performed using 20 Wg of total RNAs from
breast tumor tissues (T) and adjacent normal tissues (N) with efp
and GAPDH RNA probes. The ratio of the amount of efp in a tu-
mor to adjacent normal tissue (T/N) is shown above.
Fig. 3. Estrogen responsiveness of human efp in MCF-7 breast can-
cer cells. A: Estrogen-induced expression of efp mRNA. MCF-7
cells were treated for the indicated hours with or without 1038 M
17L-estradiol and total RNAs were extracted. The RNase protection
assay was carried out using 20 Wg of total RNAs with efp and
GAPDH RNA probes. The intensity of each signal of efp and
GAPDH was measured by phosphoimager analysis and efp mRNA
levels were normalized using GAPDH mRNA levels as reference.
Each experiment was carried out in triplicate and the results are
shown as mean+S.D. *P6 0.01. B: Estrogen-induced promoter ac-
tivity of efp in MCF-7 cells. The structures of the CAT reporter
plasmids are shown schematically (left) and their relative CAT activ-
ities are shown on the right of each construct. GC-box, E-box and
ERE are shown by the open circle, open box and ¢lled triangles, re-
spectively. Each experiment was carried out in triplicate and the re-
sults are shown as mean+S.D. *P6 0.01 compared to transfections
without estrogen.
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indispensable for the estrogen-induced activity of the human
efp promoter. In addition, pCAThe-173mERE containing the
ERE in the 3P-UTR of the mouse efp gene, which contains a
1 bp mismatch to the consensus ERE (GGTCANNNTG-
ACC), could also respond to estrogen, albeit to a lower de-
gree.
4. Discussion
The human efp gene expands approximately 25 kb of ge-
nomic DNA and has nine exons. Genetic alteration is a com-
mon event in breast cancer. Particularly, gene ampli¢cations
and allelic losses are frequently found on the long arm of
chromosome 17 on which the efp gene is mapped [13]. For
example, the BRCA1 gene, mapped at chromosome 17q21, is
a well-known breast cancer susceptibility gene involved in
DNA repair, transcription regulation and apoptosis [14,15].
The c-ErbB-2 gene, also mapped at chromosome 17q21, is a
proto-oncogene encoding a tyrosine kinase receptor and is
ampli¢ed in breast cancer [16]. The information of the ge-
nomic organization or exon/intron junction of the efp gene,
which was mapped to the 17q23.1 region by FISH [17], will be
useful for genetic analysis of breast cancer.
We have shown here a rather robust expression of the efp
mRNA in human breast tumors and in MCF-7 breast cancer
cells. Moreover, the expression of the efp mRNA in MCF-7
cells was elevated as early as 30 min after estrogen treatment,
in line with the notion that the efp is directly regulated by
estrogen. Efp is a member of the RING ¢nger protein family
[6] which appears to be involved in transcription, di¡erentia-
tion as well as oncogenesis. For example, PML [18] is fused to
the retinoic acid receptor K in acute promyelocytic leukemia
and BRCA1 [14] is mutated in some early-onset breast cancers
and ovarian cancer. Thus, the efp may function as an ER
primary responsive gene and mediate an estrogen action lead-
ing to growth in cancer. Indeed, the estrogen-responsive pro-
Fig. 4. Efp promoter with ERE responds to both ERK and ERL. CAT reporter plasmids containing human efp promoter regions were trans-
fected together with no ER expression vector (A), 1 Wg of pCXN2-hERK (B) or 1 Wg of pCXN2-hERL (C) into 293T cells. Each experiment
was carried out in triplicate and the results are shown as mean+S.D. *P6 0.01 compared to transfections without estrogen.
Fig. 5. Function of ERE in the 3P-UTR of the human and mouse efp genes for estrogen-induced transactivation. pCAThe-173ERE, pCAThe-
173mutERE1, pCAThe-173mutERE2 and pCAThe-173mERE (see Section 2) were transfected together with pCXN2-hERK into MCF-7 cells
(A) and 293T cells (B) or together with pCXN2-hERL into 293T cells (C). Each experiment was carried out in triplicate and the results are pre-
sented as fold induction compared to transfections without estrogen.
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liferation of uterine cells which express abundant ERK was
impaired in efp knockout mice, suggesting that the efp is a
mediator of cell growth [6]. We also found that the efp was
expressed in some ovarian cancers by RNase protection assay
(data not shown) and, recently, it was shown that the efp was
upregulated by bile acids in gastric cancer cells in which bile
acids appeared to be involved in carcinogenesis [19]. Further
studies will provide useful information about the contribution
of the efp gene in various cancers.
CAT analysis of the estrogen responsiveness of the efp pro-
moter demonstrated that the ERE in the 3P-UTR e⁄ciently
functions as an enhancer. Recently, a second estrogen recep-
tor, ERL, has been isolated and its tissue distribution and
ligand speci¢city have been shown to be di¡erent from those
of ERK [20,21], suggesting di¡erential biological roles of ERK
and ERL. It is reported that some human breast tumors ex-
press ERK and/or ERL [22,23]. The efp promoter could be
enhanced by both ERK and ERL under estrogen treatment,
whereas it was not observed when neither ER expression vec-
tor was transfected. Thus, the efp could respond to estrogen
as a common downstream gene of ERK and ERL and may
mediate estrogen actions in both ERK- and ERL-positive
breast tumors.
Taking together the results presented here and described
previously [7], we consider the mechanism of transcription
regulation of the human efp gene to be as follows. The E-
box-bound USF is indispensable for the basal activity in the
TATA-less human efp promoter [7]. USF is also known to
recognize an initiator sequence around a transcription initia-
tion site and to interact with basal transcription factors [24].
Moreover, both ERK and ERL could further regulate the
promoter activity through the ERE in the 3P-UTR. We as-
sume that the efp acts as one of the primary estrogen respon-
sive genes in ERK- and/or ERL-positive breast tumors and
would mediate estrogen functions such as cell proliferation.
Some transcription cofactors of ER as well as negative and
positive regulatory factors described above may be involved in
the regulation although their mechanisms remain to be deter-
mined. Studies of transcriptional regulation of estrogen-re-
sponsive genes such as efp will help clarify the mechanism
of estrogen actions in cancer.
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